LNPs

MagicRNA holds a comprehensive ionizable amino lipid library composed of more than 15,000 lipids. MagicRNA LNPs feature appropriate particle size and PDI, high entrapment efficiency, excellent morphology and druggability, with freeze-thaw and long-term stability basically the same as SM-102-LNP.

In C57BL/6 mice, MagicRNA LNPs exhibit higher expression levels in both intramuscular (I.M.) and intravenous (I.V.) injection compared with commercial lipid (MC3, ALC-0315, and SM-102) LNPs.

Publications

• The New England Journal of MedicineIn Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
• Antiviral ResearchMpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice
• Advanced Healthcare MaterialsDelivery of mRNA Vaccine with 1,2-diesters-derived Lipids Elicits Fast Liver Clearance for Safe and Effective Cancer Immunotherapy
• OncoImmunologyNovel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity
• Pharmaceuticsα-Lactalbumin mRNA-LNP Evokes an Anti-Tumor Effect Combined with Surgery in Triple-Negative Breast Cancer
• Acta BiomaterialiaPersonalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models